A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia

Clinical trial NCT07604064 · RECRUITING

Trial details

NCT number: NCT07604064
Sponsor: Kissei Pharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia

Start date: 2026-06-01
Primary completion: 2030-09-01
Enrollment: 3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.